![](https://endpts.com/wp-content/uploads/2022/07/Neil-Kumar-Endpoints-at-BIO22-feature.jpg)
Neil Kumar, BridgeBio CEO (J.T. MacMillan Photography for Endpoints News)
BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
BridgeBio released additional analyses of its Phase 3 study of acoramidis in ATTR-CM on Wednesday, spotlighting the link between serum transthyretin (TTR) levels and the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.